20106 results for «»
20106 results
Featured cases - Combined valve interventions (Part 1)
24 Nov 2024 – From PCR London Valves 2024
Explore a captivating collection of featured cases showcasing the art of combined valve interventions. Witness precision and planning in dual-valve symphony, innovative solutions for complex mitral annular calcification, and unexpected twists where the results defy expectations. Delve into transcatheter approaches for aortic bioprosthesis degeneration, mitral repair...
From index procedure to re-valving with a novel self-expanding valve
25 Nov 2024 – From PCR London Valves 2024
Watch this simulation-based symposium to explore the value of the Index Procedure in achieving optimal outcomes during the initial implant, crucial for preventing paravalvular leak, pacemaker dependency, and ensuring precise commissural alignment for coronary access. Discover how the ACURATE neo2/PRIME offers excellent coronary access with its...
Featured Cases - TAVI in patients with challenging vascular access
24 Nov 2024 – From PCR London Valves 2024
Delve into a collection of captivating TAVI cases that push the boundaries of vascular access challenges. Witness how interventionists navigate complex aortic anatomies, dissections, and rare genetic diseases to deliver life-saving care. Explore innovative approaches such as transbrachial TAVI, transcarotid access, and valve-in-valve TAVI. This session...
Hotline - ACURATE neo2 under-expansion in the ACURATE IDE study: a post-hoc analysis
21 May 2025 – From EuroPCR 2025
Howard Herrmann and Raj Makkar discuss a sub-study of the ACURATE IDE trial, which examined valve under-expansion detected by fluoroscopy. Among 1,500 patients with aortic stenosis, 22 % of ACURATE neo2 valves showed under-expansion, often linked to heavy valve calcification.
Patients with under-expanded valves faced higher risks...
What are the essentials of the provisional strategy for non-left main true bifurcation lesions?
21 May 2025 – From EuroPCR 2025
Giuseppe Di Gioia and Jens Flensted Lassen explore the essentials of the provisional stenting strategy for non-left main true bifurcation lesions. This stepwise approach offers simplicity while preserving flexibility: start with one stent in the main vessel, and keep the option open for a second if...
First guidelines for the treatment of LM disease issued by SOLACI and SIAC
22 May 2025 – From EuroPCR 2025
During EuroPCR 2025, Cleverson Zukowski and Pablo Lamelas introduce a landmark initiative: the first clinical guidelines for left main disease specifically developed for Latin America.
Published by the Latin American Society of Interventional Cardiology (SOLACI) and the Interamerican Society of Cardiology (SIAC), these recommendations aim to support...
How will EARLY-TAVI and NOTION-3 impact TAVI practice?
21 May 2025 – From EuroPCR 2025
When is the right time to perform TAVI—and how should coexisting coronary artery disease be managed? In this interview, Liesbeth Rosseel, Davide Capodanno, and Michael Joner tackle these two timely questions. They share key takeaways from the EARLY-TAVI trial, which demonstrated reduced rehospitalisation with early intervention...
Major LBTs from EuroPCR 2025 - Meta-Analysis of individual patient data from the PROTECTED TAVR and BHF PROTECT-TAVI studies
22 May 2025 – From EuroPCR 2025
Stroke remains one of the most feared complications of TAVI—for both patients and physicians. In this EuroPCR 2025 video interview, Bernard Prendergast and Rajesh Kharbanda examine the role of cerebral protection during TAVI procedures, in light of two randomised trials: PROTECTED TAVR and BHF PROTECT-TAVI. While...
Major EuroPCR 2025 LBT - 4D-ACS: one-month DAPT followed by dose reduction of prasugrel after drug-coated stent insertion in acute coronary syndrome
21 May 2025 – From EuroPCR 2025
In this EuroPCR 2025 interview, Davide Capodanno and Woong Chol Kang discuss antithrombotic therapy in patients with acute coronary syndromes, focusing on the design and outcomes of the 4D-ACS trial. They describe the patient population enrolled in the study and introduce the two de-escalation strategies investigated:...
Benefits of IVUS plus near-infrared spectroscopy in detecting and managing vulnerable plaques
21 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Nilesh Pareek and Thomas Keeble discuss the clinical value and future potential of NIRS IVUS, a dual-modality imaging system developed by Nipro that combines intravascular ultrasound with near-infrared spectroscopy.
The Makoto™ system and Dualpro™ catheter allow real-time identification of lipid-rich plaques by providing both...
Learnings from Evolut Low Risk 5-year and SMART 2-year trials : from evidence to practice
21 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Angela McInerney, Didier Tchétché, and Ole De Backer discuss key results from the SMART and Evolut Low Risk trials. The SMART trial compared balloon-expandable and self-expanding valves in small annulus patients, showing better hemodynamics with the Evolut platform at 2 years. The Evolut...
Redo TAVI: how to treat different TAVI platforms when they fail?
22 May 2025 – From EuroPCR 2025
In this discussion, Tanja Rudolph, Dan Blackman, and Radoslaw Parma take a deep dive into the current understanding of redo TAVR.
Together, they address the main challenges faced in repeat procedures - chiefly, the risk of coronary obstruction and the importance of preserving coronary access, alongside strategies...
Advances in the development of drug-coated balloon
22 May 2025 – From EuroPCR 2025
Join Florim Cuculi and Rony Mathew at this EuroPCR 2025 roundtable to assess the evolution of drug-coated balloons (DCBs) and their role in daily practice.
DCBs offer a compelling alternative to stent implantation in selected cases. However, they are not interchangeable—each is built using different drugs, carriers,...
How to manage the challenges of TAVI in bicuspid disease?
22 May 2025 – From EuroPCR 2025
How should TAVI be adapted to the unique challenges of bicuspid aortic valve disease? In this EuroPCR 2025 discussion, Chiara De Biase, Kentaro Hayashida, and Didier Tchetche explore the key anatomical and procedural considerations for tailoring treatment. From selecting which bicuspid anatomies are suitable for TAVI...
Learnings from LANDMARK and Compare-TAVI at 3 years
22 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Andreas Baumbach, Christian Juhl Terkelsen and Didier Tchetche reviewed the latest findings from the LANDMARK and Compare-TAVI 1 trials—both focused on the performance of the Myval balloon-expandable valve.
LANDMARK compared Myval and Myval Octacor to leading self-expanding valves in a randomised controlled trial. At...
Focal or diffuse coronary disease: how can PPG measurement contribute to clinical decision-making?
22 May 2025 – From EuroPCR 2025
How can physiology guide treatment decisions beyond ischemia detection? In this round-table recorded at EuroPCR 2025, Thomas Engstrøm, Carlos Collet and Jeroen Sonck examine how pullback pressure gradient (PPG) makes it possible to identify the distribution pattern of coronary artery disease—focal or diffuse—based on a continuous...
Latest learnings on the treatment of asymptomatic severe aortic stenosis from the EARLY TAVR
22 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Christopher Cook, Philippe Genereux, and Victoria Delgado discuss key results from the EARLY TAVR study.
In asymptomatic patients with severe aortic stenosis, early intervention was associated with significantly less cardiac damage at 2 years, compared to a surveillance strategy that led to extensive damage...
Arnaud Bertrand
Montbonnot Saint Martin, France
Mariama Akodad
Massy, France
Rasha Al-Bawardy
Jeddah, Saudi Arabia